Bioheart Inc, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.
Approximately four years ago in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell(TM)) in congestive heart failure patients. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.
This fat was processed to obtain the stromal vascular fraction (SVF) which